GALVECTA
VILDAGLIPTIN · by PHARMEVO
Composition
Tab 50 mg: Vildagliptin 50 mg.
Indications & Dosage
Type 2 diabetes mellitus as monotherapy or in combination with metformin or pioglitazone (dual therapy) or in combination with both metformin and a sulfonylurea (triple therapy) or in combination with insulin (with or without metformin) to achieve adequate glycaemic control: Adult: 50 mg twice daily Type 2 diabetes mellitus in combination with sulfonylurea (if metformin inappropriate): Adult: 50 mg daily, dose to be taken in the morning Dose of concomitant sulfonylurea or insulin may need to be reduced. Children: Not recommended.
Contraindications
Ketoacidosis, severe heart failure, severe hepatic impairment.
Precautions
Renal impairment, reduce dose to 50mg once daily if eGFR less than 50 ml/minute/1.73m2, elderly, monitor liver function before treatment and every 3 months for first year and periodically thereafter.
Pregnancy
Contraindicated in pregnancy.
Lactation
Contraindicated or not recommended.
Side Effects
Peripheraloedema, lactic acidosis (discontinue), asthenia, dizziness, headache, tremor, arthralgia, constipation, hypoglycaemia, Rare: Hepatic dysfunction, upper respiratory tract infection, nasopharyngitis, exfoliativeskin reactions and pancreatitis (discontinue).